Exelixis Inc
1EXEL
Company Profile
Business description
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Contact
1851 Harbor Bay Parkway
AlamedaCA94502
USAT: +1 650 837-7000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,077
Stocks News & Analysis
stocks
ASX utility share downgraded as electricity prices fall
Falling electricity prices weigh on earnings outlook for utility provider.
stocks
Chart of the Week: AI market leader is now surprisingly cheap
This AI beneficiary may still be one of the market’s most compelling bargains.
stocks
Weekly earnings wrap: Rio Tinto leads the way
A closer look at the key earnings results from the first week of August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,452.00 | 42.10 | 0.45% |
| CAC 40 | 8,728.42 | 59.13 | 0.68% |
| DAX 40 | 26,205.40 | 79.10 | 0.30% |
| Dow JONES (US) | 54,164.51 | 184.61 | -0.34% |
| FTSE 100 | 10,883.06 | 5.24 | -0.05% |
| HKSE | 25,530.28 | 385.54 | -1.49% |
| NASDAQ | 26,424.61 | 61.17 | 0.23% |
| Nikkei 225 | 65,683.26 | 617.18 | -0.93% |
| NZX 50 Index | 13,958.06 | 39.12 | -0.28% |
| S&P 500 | 7,727.52 | 3.97 | 0.05% |
| S&P/ASX 200 | 9,271.60 | 41.80 | 0.45% |
| SSE Composite Index | 3,900.35 | 21.92 | 0.57% |